These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31308206)

  • 1. Changes in the Presentation of Incident Gout and the Risk of Subsequent Flares: A Population-based Study over 20 Years.
    Elfishawi MM; Zleik N; Kvrgic Z; Michet CJ; Crowson CS; Matteson EL; Bongartz T
    J Rheumatol; 2020 Apr; 47(4):613-618. PubMed ID: 31308206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and risk factors of gout flares in a large population-based cohort of incident gout.
    Rothenbacher D; Primatesta P; Ferreira A; Cea-Soriano L; Rodríguez LA
    Rheumatology (Oxford); 2011 May; 50(5):973-81. PubMed ID: 21228059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalization Increases the Risk of Acute Arthritic Flares in Gout: A Population-based Study over 2 Decades.
    Zleik N; Elfishawi MM; Kvrgic Z; Michet CJ; Crowson CS; Matteson EL; Bongartz T
    J Rheumatol; 2018 Aug; 45(8):1188-1191. PubMed ID: 29961683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-based Study over 20 Years.
    Elfishawi MM; Zleik N; Kvrgic Z; Michet CJ; Crowson CS; Matteson EL; Bongartz T
    J Rheumatol; 2018 Apr; 45(4):574-579. PubMed ID: 29247151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical activity measured using wearable activity tracking devices associated with gout flares.
    Elmagboul N; Coburn BW; Foster J; Mudano A; Melnick J; Bergman D; Yang S; Chen L; Filby C; Mikuls TR; Curtis JR; Saag K
    Arthritis Res Ther; 2020 Aug; 22(1):181. PubMed ID: 32746893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
    Schumacher HR; Sundy JS; Terkeltaub R; Knapp HR; Mellis SJ; Stahl N; Yancopoulos GD; Soo Y; King-Davis S; Weinstein SP; Radin AR;
    Arthritis Rheum; 2012 Mar; 64(3):876-84. PubMed ID: 22223180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccination and Gout Flare Risk in Patients With Infrequent or Frequent Flares: A Prospective Cohort Study.
    He Y; Xue X; Dalbeth N; Terkeltaub R; Chen Y; Yan F; Pang L; Li X; Yuan X; Cheng X; Li C; Sun M
    Arthritis Care Res (Hoboken); 2024 Jan; 76(1):131-139. PubMed ID: 37553607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Events and Gout Flares.
    Anderson JL; Knowlton KU
    JAMA; 2022 Aug; 328(5):425-426. PubMed ID: 35916865
    [No Abstract]   [Full Text] [Related]  

  • 10. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
    Bakris GL; Doghramji PP; Keenan RT; Silber SH
    Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of gout: a 57-year-old man with a history of podagra, hyperuricemia, and mild renal insufficiency.
    Shmerling RH
    JAMA; 2012 Nov; 308(20):2133-41. PubMed ID: 23188030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of claims-based algorithms for gout flares.
    MacFarlane LA; Liu CC; Solomon DH; Kim SC
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):820-6. PubMed ID: 27230083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data.
    Koto R; Nakajima A; Horiuchi H; Yamanaka H
    Mod Rheumatol; 2021 Jan; 31(1):261-269. PubMed ID: 32552370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gout].
    Tausche AK
    Internist (Berl); 2021 May; 62(5):513-525. PubMed ID: 33721041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on gout and hyperuricemia.
    Baker JF; Schumacher HR
    Int J Clin Pract; 2010 Feb; 64(3):371-7. PubMed ID: 19909378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population.
    Primatesta P; Plana E; Rothenbacher D
    BMC Musculoskelet Disord; 2011 May; 12():103. PubMed ID: 21599917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The year in gout - 2010-2011.
    Crittenden DB; Pillinger MH
    Bull NYU Hosp Jt Dis; 2011; 69(3):257-63. PubMed ID: 22035440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.